Stifel Financial’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Stifel Financial’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-362	Closed	-$79K	–	2837
2018 Q3	$79K	Buy	+362	New	+$869K	﹤0.01%	2693
2016 Q4	–	Sell	-36	Closed	-$39K	–	2568
2016 Q3	$39K	Hold	36	–	–	﹤0.01%	2340
2016 Q2	$28K	Hold	36	–	–	﹤0.01%	2464
2016 Q1	$25K	Hold	36	–	–	﹤0.01%	2185
2015 Q4	$35K	Buy	36 +10	+38%	+$13.2K	﹤0.01%	2295
2015 Q3	$28K	Buy	26 +12	+86%	+$17.5K	﹤0.01%	2200
2015 Q2	$29K	Buy	14 +7	+100%	+$9.95K	﹤0.01%	2313
2015 Q1	$7K	Hold	7	–	–	﹤0.01%	2296
2014 Q4	$7K	Hold	7	–	–	﹤0.01%	2305
2014 Q3	$7K	Sell	7 -9	-56%	-$13.3K	﹤0.01%	2212
2014 Q2	$30K	Hold	16	–	–	﹤0.01%	2162
2014 Q1	$34K	Buy	+16	New	+$39.9K	﹤0.01%	2052

Other funds holding ONCT

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stifel Financial's ONCT Position: Q4 2018 in Review

Stifel Financial sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2018, closing a stake of 362 shares — an estimated $79K sold.

Stifel Financial first reported a position in ONCT in Q1 2014 and held it in 12 quarters. The position peaked at $79K in Q3 2018. 43 funds tracked by Wall St. Rank hold ONCT as of Q4 2018.

Stifel Financial reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Stifel Financial sold 362 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $79K.
Stifel Financial first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2014 and held it in 12 quarters.
Stifel Financial's Oncternal Therapeutics, Inc. Common Stock position peaked at $79K in Q3 2018.
43 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Stifel Financial's 13F filing for Q4 2018, filed 13 Feb 2019.